379 related articles for article (PubMed ID: 17419696)
1. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer.
Chen CH; Shun CT; Huang KH; Huang CY; Tsai YC; Yu HJ; Pu YS
BJU Int; 2007 Aug; 100(2):281-6; discussion 286. PubMed ID: 17419696
[TBL] [Abstract][Full Text] [Related]
2. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder.
Fleshner N; Garland J; Moadel A; Herr H; Ostroff J; Trambert R; O'Sullivan M; Russo P
Cancer; 1999 Dec; 86(11):2337-45. PubMed ID: 10590376
[TBL] [Abstract][Full Text] [Related]
3. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
4. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease.
Chen CH; Shun CT; Huang KH; Huang CY; Yu HJ; Pu YS
Urology; 2008 Jun; 71(6):1155-60. PubMed ID: 18372011
[TBL] [Abstract][Full Text] [Related]
7. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.
Lammers RJ; Witjes WP; Hendricksen K; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2011 Oct; 60(4):713-20. PubMed ID: 21794974
[TBL] [Abstract][Full Text] [Related]
8. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
[TBL] [Abstract][Full Text] [Related]
9. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer.
Rink M; Xylinas E; Babjuk M; Hansen J; Pycha A; Comploj E; Lotan Y; Sun M; Karakiewicz PI; Abdennabi J; Fajkovic H; Loidl W; Chun FK; Fisch M; Scherr DS; Shariat SF
J Urol; 2012 Dec; 188(6):2120-7. PubMed ID: 23083868
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
12. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
[TBL] [Abstract][Full Text] [Related]
13. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
[TBL] [Abstract][Full Text] [Related]
14. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Serretta V; Altieri V; Morgia G; Di Lallo A; Carrieri G; Allegro R;
Urology; 2013 Feb; 81(2):277-81. PubMed ID: 23374781
[TBL] [Abstract][Full Text] [Related]
15. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
16. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology.
Raman JD; Ng CK; Boorjian SA; Vaughan ED; Sosa RE; Scherr DS
BJU Int; 2005 Nov; 96(7):1031-5. PubMed ID: 16225523
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
19. Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder.
Raitanen MP; Tammela TL
Ann Chir Gynaecol; 1995; 84(1):37-41. PubMed ID: 7645909
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
Schmidbauer J; Lindenau G
Curr Opin Urol; 2008 Sep; 18(5):504-7. PubMed ID: 18670275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
